Moran, C and Callisaya, ML and Srikanth, V and Arvanitakis, Z, Diabetes therapies for dementia, Current Neurology and Neuroscience Reports, 19, (8) Article 58. ISSN 1528-4042 (2019) [Refereed Article]
Copyright 2019 Springer Science-Business Media, LLC, part of Springer Nature
Recent Findings: Results from basic laboratory research support the potential for commonly-used medications for T2D, including those with direct glucose-lowering properties, to have a beneficial effect on brain health. However, human studies have been mostly observational in nature and report conflicting results. Preliminary data suggest that intranasal insulin, metformin, and GLP-1 agonists show promise for dementia, but confirmatory evidence for their benefit in dementia is still lacking.
Summary: Current evidence does not support the repurposing of T2D medications for dementia risk reduction or management. Research in the field of T2D and dementia is active, and further data are required before definitive conclusions can be drawn.
|Item Type:||Refereed Article|
|Keywords:||dementia, drugs, type 2 diabetes|
|Research Division:||Medical and Health Sciences|
|Research Group:||Clinical Sciences|
|Research Field:||Geriatrics and Gerontology|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|UTAS Author:||Moran, C (Dr Chris Moran)|
|UTAS Author:||Callisaya, ML (Dr Michele Callisaya)|
|UTAS Author:||Srikanth, V (Dr Velandai Srikanth)|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page